2IVB Stock Overview
Develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Indivior PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£7.75 |
| 52 Week High | UK£18.30 |
| 52 Week Low | UK£6.80 |
| Beta | 0.32 |
| 1 Month Change | -13.89% |
| 3 Month Change | -31.42% |
| 1 Year Change | -57.65% |
| 3 Year Change | -61.15% |
| 5 Year Change | n/a |
| Change since IPO | 39.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2IVB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.3% | 2.1% | 2.4% |
| 1Y | -57.7% | -23.4% | 2.0% |
Return vs Industry: 2IVB underperformed the German Pharmaceuticals industry which returned -23.4% over the past year.
Return vs Market: 2IVB underperformed the German Market which returned 2% over the past year.
Price Volatility
| 2IVB volatility | |
|---|---|
| 2IVB Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 2IVB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2IVB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1,041 | Mark Crossley | www.indivior.com |
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
Indivior PLC Fundamentals Summary
| 2IVB fundamental statistics | |
|---|---|
| Market cap | €987.94m |
| Earnings (TTM) | -€42.22m |
| Revenue (TTM) | €1.04b |
0.9x
P/S Ratio-23.4x
P/E RatioIs 2IVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2IVB income statement (TTM) | |
|---|---|
| Revenue | US$1.19b |
| Cost of Revenue | US$209.00m |
| Gross Profit | US$979.00m |
| Other Expenses | US$1.03b |
| Earnings | -US$48.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 82.41% |
| Net Profit Margin | -4.04% |
| Debt/Equity Ratio | -162.4% |
How did 2IVB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 11:13 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indivior PLC is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graham Glyn Parry | BofA Global Research |
| Brian White | Cantor Fitzgerald Europe |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |